NeurologyLive® Friday 5 — March 14, 2025

Author(s):

NeurologyLive® Staff

Key Takeaways

Emerging trends in multiple sclerosis are highlighted at the 2025 ACTRIMS Forum, focusing on innovative tracks and clinical insights.
FDA approval of suzetrigine introduces a selective, nonaddictive alternative to opioids for acute pain management.
ESCAPE-MeVO trial results stress the impact of anesthesia rates and thrombectomy techniques in stroke treatment.
Advances and challenges in gene therapy for neuromuscular disorders are discussed at the 2025 MDA Clinical & Scientific Conference.
Rapid advancements in translating genetic research into ALS treatments are noted, with ongoing challenges remaining.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 14, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, February 2025: Approvals, Designations, and Acceptances

Catch up on any of the neurology news headlines you may have missed over the course of February 2025, compiled all into one place by the NeurologyLive team.

2: Blueprints for Better Care: 2024 Neurology Guideline Highlights

Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.

3: Special Episode: FDA Approves Tenecteplase for Acute Ischemic Stroke

Mind Moments^®, a podcast from NeurologyLive, brings you an exclusive interview with Bijoy Menon, MD, MSc, FRCPC. [LISTEN TIME: 18 minutes]

4: NeuroVoices: Tanya Simuni, MD, FAAN, on Using the Neuronal α-Synuclein Disease Integrated Staging System Framework to Advance Parkinson Disease Staging

The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.

NeuroVoices: Tanya Simuni, MD, FAAN, on Using the Neuronal α-Synuclein Disease Integrated Staging System Framework to Advance Parkinson Disease Staging

5: Challenges and Research Priorities for Pediatric MOGAD: Kelsey Poisson, MD

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody-associated disease. [WATCH TIME: 3 minutes]